We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Humans Can Acquire Immunity to Hepatitis C

By Biotechdaily staff writers
Posted on 24 May 2002
A study has found that humans can acquire immunity to the hepatitis C virus (HCV), suggesting that vaccines could be used to protect those with the virus from long-term complications. More...
Conducted by researchers at Johns Hopkins Medical School (Baltimore, MD, USA), the study was published in the April 26, 2002, issue of The Lancet.

The researchers compared the incidence and persistence of HCV in 164 people whose blood tests revealed no evidence of prior HCV infection and 98 people who had been infected in the past but were not infected at the time of the study. Previously infected people were almost half as likely to develop new infections as those never infected (12% vs 21%). Among HIV-1 negative people, those previously infected were 12 times less likely to develop infection than those infected for the first time. The results mirrored those of chimpanzee studies, which found that animals previously infected or vaccinated could be re-infected but their infections were less likely to persist, compared to animals infected for the first time.

"Our findings indicate that vaccines should be developed to reduce the burden of liver disease associated with hepatitis C infection,” said David. L. Thomas, associate professor of medicine at Hopkins and lead author of the study. About 170 million people worldwide have been infected with HCV, and about 85% of them develop persistent infection and are at risk of serious complications such as liver cirrhosis and liver cancer, according to Dr. Thomas. Recent vaccine research in primates is showing promise.




Related Links:
Johns Hopkins

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.